1. Home
  2. RUBI vs PTIX Comparison

RUBI vs PTIX Comparison

Compare RUBI & PTIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

RUBI

Rubico Inc.

N/A

Current Price

$1.11

Market Cap

3.1M

ML Signal

N/A

Logo Protagenic Therapeutics Inc.

PTIX

Protagenic Therapeutics Inc.

HOLD

Current Price

$1.41

Market Cap

3.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
RUBI
PTIX
Founded
N/A
1994
Country
Marshall Islands
United States
Employees
N/A
N/A
Industry
Marine Transportation
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.1M
3.0M
IPO Year
N/A
2016

Fundamental Metrics

Financial Performance
Metric
RUBI
PTIX
Price
$1.11
$1.41
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
807.3K
93.2K
Earning Date
05-06-2020
11-26-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$24,139,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$0.42
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.01
$1.12
52 Week High
$200.70
$14.28

Technical Indicators

Market Signals
Indicator
RUBI
PTIX
Relative Strength Index (RSI) N/A 37.24
Support Level N/A $1.12
Resistance Level N/A $1.68
Average True Range (ATR) 0.00 0.13
MACD 0.00 0.03
Stochastic Oscillator 0.00 35.96

Price Performance

Historical Comparison
RUBI
PTIX

About RUBI Rubico Inc.

Rubico Inc operates as a holding company. It is an eco-conscious international crude oil shipping company. The company's primary business is the ownership and operation of an eco-conscious fleet of tanker vessels designed for enhanced fuel efficiency, reduced greenhouse emissions, and a wide range of environmentally friendly technologies.

About PTIX Protagenic Therapeutics Inc.

Protagenic Therapeutics Inc is a biopharmaceutical company focused on the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. It provides treatments for mood, anxiety, depression, and neurodegenerative disorders by using peptide-based and brain-active therapeutics. The company's main compound, PT00114, is a synthetic form of Teneurin Carboxy-terminal Associated Peptide, an endogenous brain signaling peptide that can dampen overactive stress responses. It has also created a portfolio of novel neuropeptides that are in various stages of development and preclinical evaluation for the treatment of mood disorders.

Share on Social Networks: